Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...

Semaglutide is part of a group of medicines called GLP-1 receptor agonists, commonly used to manage type 2 diabetes. In recent years, it has also gained worldwide attention for helping with weight ...

JDK 26 moves to general production availability. This short-term release is backed by six months of Premier-level support. Java Development Kit (JDK) 26, the latest standard Java release from Oracle, ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

Tensions in the Strait of Hormuz are raising alarms about the stability of global pharmaceutical supply chains, with potential implications for the U.S. generic drug market, which relies heavily on ...

A newly-formed Canadian pharmaceutical company is vying to break into the market with a generic version of one of the most well-known prescription drugs in the world: Ozempic. “You could say we’re ...

On Feb. 27, reporters Kelly Grant and Chris Hannay answered reader questions on the rise of Ozempic and similar drugs in Canada, what experts are saying about the health risks and benefits and how it ...

The Senate Republican campaign chair has a stark warning for his party as the GOP defends its 53-47 majority in the chamber in this year's midterm elections. National Republican Senatorial Committee ...